Objective: To investigate the relationship of renal parenchymal thickness and the risk of developing post-procedure hematoma. Methods: Ultrasound-guided percutaneous renal biopsy was performed in 122 patients who underwent percutaneous kidney biopsy between January 2013 and -December 2013 at Tai-he hospital. Post-biopsy renal ultrasound was performed within 12 h after the biopsy to assess the presence of hematoma in biopsied kidney. Logistic regression analysis was used to determine the effect of parenchymal thickness on formation of hematoma adjusted for other nonstructural patient-related factors such as age, sex, systolic and diastolic blood pressure, serum creatinine, and urea. Results: The incidence of complication was 19.4%, all of which were hematoma less than 5 cm. None of the patients went on to have severe complications that required clinical, surgical, or radiological intervention. Out of the collected clinical and anatomical parameters, renal parenchymal thickness of the biopsied kidney was found to be the only factor with strong association with complication risks. Conclusion: This is the first study investigating the impact of structural perimeters on complication risks of percutaneous renal biopsy. Renal parenchymal thickness is a significant predictor of presence of hematoma evident on post-biopsy ultrasound evaluation, which would be used in the early prevent the complications of percutaneous renal biopsy.

1.
Parrish AE. Complications of percutaneous renal biopsy: a review of 37 years’ experience.
Clin Nephrol
. 1992 Sep; 38(3): 135–41.
2.
Bandari J, Fuller TW, Turner Іі RM, D’Agostino LA. Renal biopsy for medical renal disease: indications and contraindications.
Can J Urol
. 2016 Feb; 23(1): 8121–6.
3.
Whittier WL, Korbet SM. Renal biopsy: update.
Curr Opin Nephrol Hypertens
. 2004 Nov; 13(6): 661–5.
4.
Roccatello, D., Sciascia S, Rossi D, Naretto C, Bazzan M, Solfietti L, Baldovino S, Menegatti E. Outpatient percutaneous native renal biopsy: safety profile in a large monocentric cohort.
BMJ Open
. 2017 Jun 21; 7(6):e015243.
5.
Waldo B, Korbet SM, Freimanis MG, Lewis EJ. The value of post-biopsy ultrasound in predicting complications after percutaneous renal biopsy of native kidneys.
Nephrol Dial Transplant
. 2009 Aug; 24(8): 2433–9.
6.
Hirano D, Fujinaga S, Nishizaki N, Kanai H, Ida H. Role of ultrasound in revealing complications following percutaneous renal biopsy in children.
Clin Nephrol
. 2013 Dec; 80(6): 426–32.
7.
Sethi I, Brier M, Dwyer A. Predicting post renal biopsy complications.
Semin Dial
. 2013 Sep-Oct; 26(5): 633–5.
8.
Shidham GB, Siddiqi N, Beres JA, Logan B, Nagaraja HN, Shidham SG, et al. Clinical risk factors associated with bleeding after native kidney biopsy.
Nephrology (Carlton)
. 2005 Jun; 10(3): 305–10.
9.
Simard-Meilleur MC, Troyanov S, Roy L, Dalaire E, Brachemi S. Risk factors and timing of native kidney biopsy complications.
Nephron Extra
. 2014 Mar; 4(1): 42–9.
10.
Tepeler A, Binbay M, Akman T, Erbin A, Kezer C, Silay MS, et al. Parenchymal thickness: does it have an impact on outcomes of percutaneous nephrolithotomy?
Urol Int
. 2013; 90(4): 405–10.
11.
Haifler M, Kutikov A. Current Role of Renal Biopsy in Urologic Practice.
Urol Clin North Am
. 2017 May; 44(2): 203–11.
12.
Corapi KM, Chen JL, Balk EM, Gordon CE. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis.
Am J Kidney Dis
. 2012 Jul; 60(1): 62–73.
13.
Stratta P, Canavese C, Marengo M, Mesiano P, Besso L, Quaglia M, et al. Risk management of renal biopsy: 1387 cases over 30 years in a single centre.
Eur J Clin Invest
. 2007 Dec; 37(12): 954–63.
14.
Bataille S, Jourde N, Daniel L, Mondain JR, Faure M, Gobert P, et al. Comparative safety and efficiency of five percutaneous kidney biopsy approaches of native kidneys: a multicenter study.
Am J Nephrol
. 2012; 35(5): 387–93.
15.
Tøndel C, Vikse BE, Bostad L, Svarstad E. Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010.
Clin J Am Soc Nephrol
. 2012 Oct; 7(10): 1591–7.
16.
Feldmann Y, Böer K, Wolf G, Busch M. Complications and monitoring of percutaneous renal biopsy – a retrospective study.
Clin Nephrol
. 2018 Apr; 89(4): 260–268.
17.
Fisi V, Mazák I, Degrell P, Halmai R, Molnár GA, Fehér E, et al. Histological diagnosis determines complications of percutaneous renal biopsy: a single-center experience in 353 patients.
Kidney Blood Press Res
. 2012; 35(1): 26–34.
18.
Prasad N, Kumar S, Manjunath R, Bhadauria D, Kaul A, Sharma RK, et al. Real-time ultrasound-guided percutaneous renal biopsy with needle guide by nephrologists decreases post-biopsy complications.
Clin Kidney J
. 2015 Apr; 8(2): 151–6.
19.
Peters B, Stegmayr B, Andersson Y, Hadimeri H, Mölne J. Increased risk of renal biopsy complications in patients with IgA-nephritis.
Clin Exp Nephrol
. 2015 Dec; 19(6): 1135–41.
20.
Yaprak M, Çakır Ö, Turan MN, Dayanan R, Akın S, Değirmen E, et al. Role of ultrasonographic chronic kidney disease score in the assessment of chronic kidney disease.
Int Urol Nephrol
. 2017 Jan; 49(1): 123–31.
21.
Zaza G, Bernich P, Lupo A; ‘Triveneto’ Register of Renal Biopsies (TVRRB). Renal biopsy in chronic kidney disease: lessons from a large Italian registry.
Am J Nephrol
. 2013; 37(3): 255–63.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.